FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine and concerns simulating panctreatopathy caused by administering a non-steroidal anti-inflammatory drug (NSAID-panctreatopathy). The method involves the oral administration of Nise® into a laboratory rat in a single dose of 5 mg/kg of animal's body weight for 21 days.
EFFECT: method provides stimulating NSAID-panctreatopathy close to real clinical conditions, when using therapeutic doses of the preparation, leading to developing pathomorphological changes specific for a toxic drug-induced pancreatic injury.
3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING ACUTE PANCREATITIS EXPERIMENTALLY | 2014 |
|
RU2542465C1 |
| METHOD OF SIMULATING GASTROPATHY | 2009 |
|
RU2424578C1 |
| THE METHOD OF MODELING OF CHEMICAL GASTRITIS | 2010 |
|
RU2442227C2 |
| GEL FORM OF NIMESULIDE POSSESSING ANTI-INFLAMMATORY AND ANALGESIC ACTION | 2015 |
|
RU2593777C1 |
| METHOD OF SIMULATION OF CHEMICAL GASTRITIS IN EXPERIMENT | 2009 |
|
RU2395125C1 |
| METHOD FOR SIMULATION OF CHEMICAL GASTRITIS | 2016 |
|
RU2657197C2 |
| METHOD FOR ENTERO- AND PANCREACTOPROTECTIVE ACTION OF NON-STEROID ANTI-INFLAMMATORY PREPARATIONS | 2012 |
|
RU2545446C2 |
| USE OF 3-AMINO-4-(5-METHYL-2-FURYL)-5,6,7,8-TETRAHYDROTHIENO[2,3-b]QUINOLIN-2-yl](PHENYL)METHANONE AS ANTI-INFLAMMATORY AGENT | 2023 |
|
RU2812570C1 |
| AGENT FOR CANCER PROPHYLAXIS | 2005 |
|
RU2290178C1 |
| AGENT FOR TREATING INFLAMMATORY DISEASES OF THE JOINTS | 2019 |
|
RU2707278C1 |
